

# Determinants of Functional Capacity and Quality of Life After Implantation of a Durable Left Ventricular Assist Device

Kiran K Mirza and Finn Gustafsson

Department of Cardiology, Rigshospitalet, Copenhagen, Denmark

## Abstract

Continuous-flow left ventricular assist devices (LVAD) are increasingly used as destination therapy in patients with end-stage heart failure and, with recent improvements in pump design, adverse event rates are decreasing. Implanted patients experience improved survival, quality of life (QoL) and functional capacity (FC). However, improvement in FC and QoL after implantation is not unequivocal, and this has implications for patient selection and preimplantation discussions with patients and relatives. This article identifies preimplantation predictors of lack of improvement in FC and QoL after continuous-flow LVAD implantation and discusses potential mechanisms, allowing for the identification of potential factors that can be modified. In particular, the pathophysiology behind insufficient improvement in peak oxygen uptake is discussed. Data are included from 40 studies, resulting in analysis of >700 exercise tests. Mean peak oxygen uptake was 13.4 ml/kg/min (equivalent to 48% of predicted value; 259 days after implantation, range 31–1,017 days) and mean 6-minute walk test distance was 370 m (182 days after implantation, range 43–543 days). Finally, the interplay between improvement in FC and QoL is discussed.

## Keywords

Predictors, 6-minute walk test, peak oxygen uptake, exercise, Kansas City Cardiomyopathy Questionnaire, Minnesota Living with Heart Failure Questionnaire, 5-Level EQ-5D

**Disclosure:** FG is a consultant for Abbott and has received speakers' fees from Abbott and Carmat. KKM has no conflicts of interest to declare.

**Received:** 5 June 2020 **Accepted:** 10 July 2020 **Citation:** *Cardiac Failure Review* 2020;6:e29. **DOI:** <https://doi.org/10.15420/cfr.2020.15>

**Correspondence:** Finn Gustafsson, Department of Cardiology, Section 2142, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. E: Finn.Gustafsson@regionh.dk

**Open Access:** This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

According to the third report from the International Society for Heart and Lung Transplantation (ISHLT) Mechanically Assisted Circulatory Support Registry, more than 15,500 left ventricular assist devices (LVADs) were implanted worldwide between 2013 and 2017.<sup>1</sup> Originally, LVADs were exclusively implanted as part of a bridge to transplantation (BTT) strategy, but in recent years a large proportion of patients undergoing LVAD implantation received the device as final treatment for advanced heart failure (HF), so-called destination therapy.

Survival rates after LVAD implantation have increased greatly over the past decade, as improvements in LVAD technology and management have resulted in a lower risk of adverse events.<sup>1–7</sup> Hence, in recent studies, 2-year survival rates range from 80% to 90%.<sup>5,8</sup> Patients treated with LVADs experience significant improvements in HF symptoms, quality of life (QoL) and functional capacity (FC), although the latter remains reduced in this patient group, especially when measured as peak oxygen uptake ( $pVO_2$ ).<sup>3,6–11</sup>

Given the increased use of LVAD as destination therapy and the long wait times for transplantation in those implanted with an LVAD as BTT, optimisation of FC and QoL is critically important.<sup>1</sup> In order to identify potential strategies to improve FC and QoL after LVAD implantation, a detailed understanding of the mechanisms behind residual impairment of these parameters is essential.


This review summarises the available evidence describing improvement in FC and QoL after LVAD implantation with the specific aim of identifying reproducible predictors of improvement in QoL and FC with the intervention.

## Methods

### Search Strategy

On 1 November 2019, a PubMed search was conducted using the search terms 'quality of life', 'EuroQoL-5 Dimensions-5 levels', 'Minnesota Living With Heart Failure', 'Kansas City Cardiomyopathy Questionnaire', 'exercise', 'six minute walk test', 'six-minute walk test', 'peak oxygen uptake', 'exercise capacity', 'peak oxygen consumption', 'exercise training', 'cardiac rehabilitation', 'ventricular assist device' and 'continuous-flow left ventricular assist device' (*Supplementary Material Table 1*). The search resulted in 609 items (*Figure 1*). After excluding studies published prior to 2006 and those written in languages other than English, the titles of 417 publications were screened by both investigators independent of each other (i.e. blinded). This process resulted in the identification of 143 publications by FG and 241 publications by KM. Mismatch and disagreement in 98 cases led to full-text review. The full text of one article could not be acquired, which resulted in its exclusion. Finally, 36 papers and four 'add-on' studies (e.g. extra studies found by reference review or other sources) were included in this narrative review.<sup>9,12–50</sup>

**Figure 1: Flowchart of the Article Selection and Review Process**



Titles of 417 publications were independently screened by both investigators (FG and KM). The limitations applied to search were publication in English and studies conducted after 2006.

**Table 1: Preimplantation Predictors of Quality of Life and Functional Capacity**

Preimplantation predictor	References
<b>Quality of life</b>	
Communication (patient–healthcare worker; patient–patient)	Modica et al. 2015 <sup>17</sup>
Patient resources	Modica et al. 2015 <sup>17</sup>
Diabetes	Kiernan et al. 2016 <sup>18</sup>
Pulmonary artery pressure	Kiernan et al. 2016 <sup>18</sup>
Right ventricular function	Kiernan et al. 2016 <sup>18</sup>
Younger age	Cowger et al. 2018 <sup>49</sup>
Higher preoperative haemoglobin	Cowger et al. 2018 <sup>49</sup>
Higher baseline quality of life score	Cowger et al. 2018 <sup>49</sup>
Ability to complete the 6MWT preoperatively	Cowger et al. 2018 <sup>49</sup>
<b>Functional capacity</b>	
Diabetes	Kiernan et al. 2016 <sup>18</sup> Hasin et al. 2012 <sup>24</sup>
Right atrial pressure	Hasin et al. 2012 <sup>24</sup>
Chronic obstructive pulmonary disease	Kiernan et al. 2016 <sup>18</sup>
AF	Gustafsson et al. 2020 <sup>48</sup>
Age	Gustafsson et al. 2020 <sup>48</sup> Schmidt et al. 2018 <sup>41</sup> Cowger et al. 2018 <sup>49</sup>
NYHA Class IV	Gustafsson et al. 2020 <sup>48</sup>
INTERMACS profile 1–2	Gustafsson et al. 2020 <sup>48</sup>
Higher baseline functional capacity	Gustafsson et al. 2020 <sup>48</sup> Cowger et al. 2018 <sup>49</sup>

See text for explanation and Supplementary Material Table 2 for a full list of studies that have investigated predictors (before and/or after implantation). 6MWT = 6 minute walk test; INTERMACS = Interagency Registry of Mechanically Assisted Circulatory Support; NYHA = New York Heart Association.

## Calculations

Mean values weighted for population size for pVO<sub>2</sub> and the 6-minute walk test (6MWT) were calculated as follows:

$$\text{Weighted mean pVO}_2 = \frac{\sum(\text{pVO}_2 \times n_{\text{pVO}_2})}{\sum N_{\text{pVO}_2}}$$

$$\text{Weighted mean } \delta\text{MWT} = \frac{\sum(\delta\text{MWT} \times n_{\delta\text{MWT}})}{\sum N_{\delta\text{MWT}}}$$

Where n refers to the number of patients in each study, while N is the total number of all studied patients. 6MWD is the distance covered in the 6MWT.

## Results and Discussion

### Functional Capacity After LVAD Implantation

The most widely accepted measures of functional capacity in HF are symptoms, measured by New York Heart Association (NYHA) class, 6MWD and pVO<sub>2</sub>. Each of these measures has its own advantages and disadvantages, such as variable reproducibility or technical demands, but all are useful and required to characterise different aspects of the exercise limitation of HF populations. Patients referred for LVAD implantation are almost invariably severely symptomatic (e.g. NYHA IIIb–IV with 6MWD <300–400 m and low pVO<sub>2</sub>). The latter is typically below 12 ml/kg/min, which is also the limit used as part of the indication for destination therapy LVAD in the US Medicare system.


In all studies of patients undergoing LVAD implantation, NYHA class improves in most patients from Class III/IV before implantation (100%) to Class I or II.<sup>9,49</sup> Studies are remarkably consistent in finding that approximately 80% of patients are in NYHA Class I–II after implantation, and the improvement in symptoms has been documented to be sustained over time.<sup>9,20,49</sup> However, some patients (<5%) remain severely symptomatic (NYHA Class IV) even 12 months after LVAD implantation.<sup>9,49</sup>

The 6MWD is widely used in LVAD recipients.<sup>9,13,16,24,31,48,49</sup> FC measured using the 6MWT prior to implantation is low (mean 6MWD 221 m [range 39–356 m]; mean 6MWD weighted for population size 215 m), and significant improvements are observed soon after implantation (mean 6MWD 373 m [range 126–531 m]; mean 6MWD weighted for population size 357 m; *Figure 2A*).<sup>9,18,24,43,49</sup> The improvement from baseline to the 6-month follow-up is, on average, +144 m (range 41–319 m; mean improvement weighted for population size 113 m), which is equivalent to an approximate 40% improvement.<sup>9,18,24,43,48,49</sup>

Improvement in the 6MWD can be difficult to interpret across different studies because some studies include mostly ambulatory patients and some include patients who would not be able to complete any exercise testing prior to implantation due to critical clinical condition (e.g. Interagency Registry of Mechanically Assisted Circulatory Support [INTERMACS] profile 1–2). In the large LVAD trials, increments in 6MWD were in the range 98–250 m from baseline to a maximum 2 years after implantation.<sup>5,9,51–60</sup> When investigating FC expressed as pVO<sub>2</sub>, the reported preimplantation values are low (mean 11 ml/kg/min [range 10.1–11.8 ml/kg/min]; mean pVO<sub>2</sub> weighted for population size 11 ml/kg/min), although improvement is observed because studies reporting pre- and postimplantation pVO<sub>2</sub> values show an improvement of approximately 20% after implantation.<sup>27,38,43</sup>

Postimplantation mean pVO<sub>2</sub> values (*Figure 2B*) vary from 8.8 to 21.4 ml/kg/min (mean pVO<sub>2</sub> weighted for population size 13.2 ml/kg/min), showing that pVO<sub>2</sub> generally remains reduced after implantation at, on average, 48% of the expected value for age and sex.<sup>12–16,21–23,25–29,31–37,39–42,44–47,61–63</sup> A considerable proportion of the variance of postimplantation pVO<sub>2</sub> between published studies can be attributed to differences in the mean age of included patients.<sup>11</sup>

Figure 2: Studies of Functional Capacity After Left Ventricular Assist Device Implantation



A: Studies reporting on 6-minute walk test (6MWT) distances. The mean walking distance after implantation with a sole LVAD was 370 m (182 days after implantation; range 43–543 days). The number of patients included in each study or study arm, as stated, is indicated by the size of the circles, with the exception of Lairez et al.<sup>39</sup> in which n for both shown study arms is set to 18, which is in fact the total study n. The mean 6MWT distance weighted for population size was 354 m. B: Studies reporting on peak oxygen uptake (pVO<sub>2</sub>). The mean reported pVO<sub>2</sub> was 13.4 ml/kg/min or 48% of predicted pVO<sub>2</sub> (values not shown). Mean pVO<sub>2</sub> weighted for population size was 13.2 ml/kg/min. The number of patients included in each is indicated by the size of the circles. AT = anaerobic threshold; AV = aortic valve; BTT = bridge to transplantation; CI = chronotropic incompetence; CR = cardiac rehabilitation; DT = destination therapy; HM3 = HeartMate 3; HMII = HeartMate II; RVEF = right ventricular ejection fraction.

Although the improvement from pre- to postimplantation FC, measured as both 6MWT and pVO<sub>2</sub>, may appear modest, these changes are much larger than the effect of other device therapies in HF, such as cardiac resynchronisation therapy or the use of vasodilators.<sup>64,65</sup> Furthermore, it should be re-emphasised that the sickest patients were excluded from studies presenting changes in FC from before to after implantation because these patients were not able to complete preimplantation measurements (e.g. because of the need for ventilator treatment or temporary mechanical circulatory support). Hence, the improvement in 6MWD and pVO<sub>2</sub> from before to after implantation is often underestimated in the literature.

### Preimplantation Predictors of Postimplantation Functional Capacity

Several studies have elucidated preimplantation determinants of postimplantation QoL and/or FC (Table 1 and Supplementary Material Table 2).<sup>17,18,24,27,38,43,48,49</sup>

Advanced age is generally a predictor of inferior outcomes in cardiovascular medicine; this also holds true for patients implanted with an LVAD. In a Multicenter Study of MAGLEV Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) substudy including 265 patients from the US, younger age was one of the strongest predictors of the 'living well on a left ventricular assist system' endpoint (6MWD >300 m and Kansas City Cardiomyopathy [KCCQ] score >50).<sup>49</sup> Confirming these findings, Martina et al. showed that HeartMate II (HMII) recipients <50 years of

age performed significantly better than LVAD recipients >50 years of age.<sup>28</sup> Several other studies have confirmed age as an independent preoperative determinant of postimplantation FC.<sup>41,46,48</sup>

Other strong preoperative predictors of FC are a lower INTERMACS profile, NYHA class, chronic obstructive pulmonary disease (COPD), diabetes and lower estimated glomerular filtration rate (eGFR).<sup>15,24,24</sup> Higher haemoglobin, eGFR and INTERMACS profile and better NYHA class at the time of implantation all reflect a general better health status, which is linked to better FC after implantation. In general, these findings are suggestive of benefits, at least in terms of FC improvement, of early implantation of LVADs in advanced HF.

The importance of perioperative diabetes has been suggested in four studies, although the largest study did not find perioperative diabetes of importance for postimplantation FC.<sup>18,24,48,66</sup> This may be due to differences in the definitions of FC used, as well as follow-up time, and more studies dissecting the interplay between diabetes and outcome after LVAD implantation are clearly needed. These studies provide important information that can be used in the clinical setting when aligning expectations with potential LVAD recipients and their families and carers.

In general, most of the studies mentioned above investigated HMI recipients in a historical period where knowledge regarding patient selection was sparse. Further, studies including data on preoperative cardiopulmonary exercise testing (which is the gold standard for studying FC), are limited.<sup>27,38,43</sup> A few studies evaluated preoperative

predictors of postimplantation FC, with FC measured as walking ability (6MWT), and these have been discussed above.<sup>28,41,46,48,49</sup>

### Relationship Between Postimplantation Functional Capacity and Adverse Events

Overall, few studies report adverse events (AEs) in relation to exercise testing in this patient group, with one case of syncope and one event of ventricular tachycardia reported, both of which were well tolerated.<sup>16,32</sup> The potential concern of AEs occurring in relation to exercise seems clinically unimportant because exercise and cardiac rehabilitation programs have been well-tolerated in both the short and long (weeks) term.<sup>19,25,42,45,49,54,56,60</sup>

An investigation of determinants of FC in 204 patients at 6 months after implantation in a substudy of the MOMENTUM 3 trial (HeartMate 3 [HM3]=114, HMII=90) found that individuals with no severe AEs (SAEs) had larger improvements in walking distance than those who experienced an SAE (e.g. the presence of a single SAE was associated with less improvement in walking distance regardless of device type).<sup>49</sup> Similarly, Imamura et al. showed that an increased pVO<sub>2</sub> was associated with lower readmission rates, underlining the clinical relevance (beyond patient mobility) of markers for exercise capacity also in the LVAD population.<sup>30</sup>

The correlation between FC and survival is well described in HF patients not receiving mechanical circulatory support, but has not been extensively studied in LVAD recipients; hence, the prognostic value of pVO<sub>2</sub> has never been reported in this patient group. In contrast, the prognostic value of the 6MWT was elucidated by Hasin et al. in 2012.<sup>24</sup> That study included 65 patients, of whom 20 were deemed poor performers (i.e. 6MWD <300 m) postoperatively. Despite similar perioperative HF severity, the poor performers showed poorer survival (i.e. 6MWD <300 m was found to be independently associated with worse survival).<sup>24</sup>

### Why Does Exercise Capacity Remain Reduced After LVAD Implantation?

#### Right and Left Ventricular Contractility

Noor et al. showed that in HMII recipients (n=30) 6 months after implantation, pump speed reduction led to significant decline in pVO<sub>2</sub> in patients with a left ventricular ejection fraction (LVEF) <40%, but did not alter FC in those with left ventricular (LV) recovery (i.e. LVEF >40%).<sup>25</sup> In 2014, in a double-blind crossover study including HMII recipients, Jung et al. showed that increasing pump speed augments pVO<sub>2</sub>, leading to the conclusion that future generations of continuous-flow LVADs should include a speed change function to improve FC in this patient group.<sup>50</sup> In 2018, these findings were confirmed in a study investigating Jarvik 2000 recipients, although that study reported a possible increased risk of AEs (obstructive sleep apnoea).<sup>40</sup>

However, conflicting data exist, because a recent retrospective study including 49 patients (HeartWare [HW]=6, HMII=43) found that neither right ventricular (RV) nor LV function was associated with the improvement in pVO<sub>2</sub>.<sup>43</sup> In accordance with these data, we recently documented that RV function, even during exercise, was not correlated with pVO<sub>2</sub> in LVAD recipients.<sup>63</sup> This is in contrast with the results obtained in HF patients not supported by an LVAD. For example, Murninkas et al. found that with every 10% worsening of RV function, pVO<sub>2</sub> worsened by 0.97 ml/kg/min.<sup>67</sup>

The studies described above are small, with considerable heterogeneity, and clearly more studies are needed to establish the importance of intrinsic cardiac contractility in the FC of LVAD recipients.

#### Chronotropic Incompetence, Arrhythmia and Pacing

Several studies have documented the negative effects of chronotropic incompetence on exercise capacity in LVAD recipients.<sup>12,21,27,38,46</sup> Depending on the definition of chronotropic incompetence, it has been reported in approximately half of all examined LVAD recipients. Chronotropic incompetence may represent a somewhat clinically modifiable factor, because many LVAD recipients receive beta-blockers, digoxin or amiodarone and are equipped with pacing devices that could be programmed to improve chronotropic competence. In fact, in a recent study in 30 patients, turning on rate response pacing in LVAD recipients with pacing devices was shown to improve FC (6MWT and treadmill FC) most clearly in patients with chronotropic incompetence.<sup>68</sup>

Perioperative AF has also been associated with lower FC after LVAD implantation.<sup>48</sup> In an analysis from the ELEVATE registry of 194 patients with an HM3, preimplantation AF was an independent predictor of poor performance (6MWD <300 m) 6 months after implantation.<sup>48,58</sup>

In patients with LVADs, LV preload is of dire importance, and patients with AF (with or without symptoms) lack the atrial kick that could impair RV function, which, in turn, affects the LV preload. Whether pharmacological therapy or AF ablation after LVAD implantation to restore sinus rhythm will improve exercise capacity has not been tested. Future studies are needed to further explore these findings to enable improvements in current technologies.

#### Pump Design, Placement and Settings

There is no evidence to suggest that one continuous-flow LVAD (e.g. axial versus centrifugal design) is associated with better postimplantation FC than other continuous-flow LVADs. Suboptimal cannula position will lead to reduced circulatory support and would likely impair FC, but this has not been studied in detail.<sup>69</sup> Increasing pump speed during exercise has been investigated in several studies and, in most, has been associated with improved FC.<sup>36,40,43,50,70</sup> Likely, a future 'smart pump' with the ability to increase pump speed in response to increased LV filling during exercise would be beneficial for the FC of LVAD recipients.

#### Comorbidities

Recently, Schmidt et al. showed that weight gain after implantation is linked to less improvement in FC (specifically, there was a negative correlation between weight gain and absolute pVO<sub>2</sub> improvement) and that pVO<sub>2</sub> plateaus after implantation with LVADs.<sup>45</sup> Regarding weight, recent reports suggest that BMI does not affect patient survival.<sup>71-73</sup> However, it could be speculated that weight gain (as seen in Schmidt et al.<sup>45</sup>) could affect specific AEs; in particular, large body size and associated comorbidities, such as diabetes, may leave the patient more prone to infection, thereby lowering FC, as discussed above.<sup>74</sup>

In studies investigating blood chemistry, haemoglobin, preoperative C-reactive protein and persistently low perioperative serum albumin concentrations were associated with lower FC after implantation.<sup>30,41,44</sup> All these parameters are adjustable. Surprisingly, B-type natriuretic peptide (BNP) was not associated with FC measured as pVO<sub>2</sub>, although increasing BNP concentrations were associated with a lower QoL.<sup>20</sup> Iron deficiency is common in LVAD recipients, but its effect on survival,

hospitalisations and FC has not been clearly established.<sup>75–77</sup> A recent pilot study of 33 patients was unable to show the expected significant improvement in the 6MWT after intravenous iron replacement 6 months after implantation.<sup>78</sup> These findings have yet to be challenged in a randomised prospective study.

Regardless of age, physical training programs (e.g. cardiac rehabilitation) after LVAD implantation have been investigated in several studies, some of which have demonstrated a beneficial effect on FC.<sup>21,26,32,37,41</sup> However, others have shown no effect of physical training on FC.<sup>13</sup> All studies have shown that physical training is safe and generally well tolerated.<sup>14,15,20–23,25,37,38,42–46,49,51–62,80–83</sup>

### Quality of Life

Overall, both large clinical studies and smaller studies included in this review have reported that QoL improves significantly after LVAD implantation.<sup>9,13–18,20,26,49,58</sup>


Different studies have assessed QoL using different QoL scores, including the 36-Item Short Form Health Survey (SF-36),<sup>13,17,26</sup> KCCQ,<sup>9,14,16,18,49</sup> Minnesota Living with Heart Failure (MLWHF) questionnaire<sup>9,15,17,18,20,45,49</sup> and the 5-Level EQ-5D (EQ-5D-5L).<sup>49,58</sup> There is no consensus as to which QoL score is superior in the LVAD population, and this complicates comparisons between studies. However, data are consistent in showing significant improvements in QoL both in the short and long term (i.e. after a minimum of 6 months follow-up), regardless of methods of quantification.<sup>9,13–18,20,26,45,49,58</sup> There is only one exception: a study of 10 LVAD recipients in the early postimplantation stage.<sup>45</sup>

The mean improvement in KCCQ score was 27 points from approximately 6 weeks to 6 months after implantation.<sup>16,49</sup> The greatest increase in KCCQ overall summary score of 178% was seen 24 months after implantation.<sup>49</sup> No differences between centrifugal and axial flow pumps have been reported regarding improvements in QoL.<sup>49</sup> In two studies that investigated QoL at either 8 weeks or 6 months after implantation, there was a mean change in SF-26 score of 9.8 points versus preimplantation.<sup>17,26</sup> The same pattern was seen when investigating QoL using the MLWHF questionnaire and the EQ-5D-5L.<sup>9,15,17,18,20,45,49,58</sup>

As earlier studies showed that a five-point change in both MLWHF and KCCQ scores is a clinically meaningful change, the improvements described above are highly important.<sup>83–85</sup>

Some factors related to postimplantation QoL, including exercise rehabilitation in different forms, comorbidities and device characteristics, have been described (*Table 1 and Supplementary Material Table 2*).<sup>13,14,16–18,20</sup> Of these, the most consistent were COPD, diabetes and FC,<sup>14,16,20</sup> although conflicting data exist.<sup>13</sup> The continued focus on alleviating AEs in LVAD recipients is highlighted by the documented correlation between QoL and AEs.<sup>49</sup> Interestingly, one

**Figure 3: Interplay Between Adverse Events, Functional Capacity and Quality of Life**



For details, refer to the text and Supplementary Material Table 2.

study highlighted the importance of the patient–physician relationship for QoL in LVAD, and it could be speculated that this may be particularly important in patients with AEs.<sup>17</sup>

Exercise capacity is closely linked to QoL. Better QoL is related to better muscular strength, treadmill time, anaerobic threshold and pVO<sub>2</sub>, all of which are factors describing aspects of FC.<sup>14,16,26</sup> The fact that increasing FC is associated with better QoL in patients implanted with a continuous-flow LVAD, as in HF patients not supported by an LVAD, highlights the need for continued focus on optimising exercise tolerance.<sup>20</sup> Indeed, an interplay between AEs, FC and QoL exists in LVAD recipients, and to improve overall QoL the other two components must be addressed (*Figure 3*).

### Conclusion

Based on a literature review, it is clear that both FC and QoL are severely impaired in advanced HF patients prior to LVAD implantation, but significant improvements are observed after implantation, even though FC remains severely reduced after implantation. Important preoperative predictors of low FC are age, diabetes, COPD, INTERMACS profile, NYHA class, AF and baseline walking distance (e.g. the ability to perform an FC test at baseline). Importantly, poor FC after LVAD implantation is closely related to QoL and is associated with the risk of AEs. These factors should be considered when considering LVAD implantation, especially as destination therapy, and reversible modifiable factors should be aggressively managed both before and after LVAD implantation. ■

- Goldstein DJ, Meyns B, Xie R, et al. Third Annual Report From the ISHLT Mechanically Assisted Circulatory Support Registry: a comparison of centrifugal and axial continuous-flow left ventricular assist devices. *J Hear Lung Transplant*. 2019;38:352–363. <https://doi.org/10.1016/j.healun.2019.02.004>; PMID: 30945637.
- de By TMMH, Mohacsi P, Gahl B, et al. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS) of the European Association for Cardio-Thoracic Surgery (EACTS): second report. *Eur J Cardiothorac Surg* 2018;53:309–16. <https://doi.org/10.1093/ejcts/ezx320>; PMID: 29029117.
- Nakatani T, Sase K, Oshiyama H, et al. Japanese registry for Mechanically Assisted Circulatory Support: first report. *J Hear Lung Transplant* 2017;36:1087–96. <https://doi.org/10.1016/j.healun.2017.08.002>; PMID: 28942783.
- Braun O, Nilsson J, Gustafsson F, et al. Continuous-flow LVADs in the Nordic countries: complications and mortality and its predictors. *Scand Cardiovasc J* 2019;53:14–20. <https://doi.org/10.1080/14017431.2019.1583365>; PMID: 30776923.
- Mehra MR, Uriel N, Naka Y, et al. A fully magnetically levitated left ventricular assist device – final report. *N Engl J Med* 2019;380:1618–27. <https://doi.org/10.1056/NEJMoa1900486>; PMID: 30883052.
- Mehra MR, Goldstein DJ, Uriel N, et al. Two-year outcomes with a magnetically levitated cardiac pump in heart failure. *N Engl J Med* 2018;378:1386–95. <https://doi.org/10.1056/NEJMoa1800866>; PMID: 29526139.
- Gustafsson F, Rogers JG. Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes. *Eur J Heart Fail* 2017;19:595–602. <https://doi.org/10.1002/ejhf.779>; PMID: 28198133.
- Saeed D, Garbade J, Gustafsson F, et al. Two-year outcomes in real world patients treated with Heartmate 3™ left ventricular assist device for advanced heart failure: data from the ELEVATE registry. *J Heart Lung Transplant* 2019;38(Suppl):S67. <https://doi.org/10.1016/j>



# Left Ventricular Assist Device

- healun.2019.01.153.
9. Rogers JG, Aaronson KD, Boyle AJ, et al. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. *Am J Coll Cardiol* 2010;55:1826–34. <https://doi.org/10.1016/j.jacc.2009.12.052>; PMID: 20413033.
  10. Kirklin JK, Pagani FD, Kormos RL, et al. Eighth annual INTERMACS report: special focus on framing the impact of adverse events. *J Heart Lung Transplant* 2017;36:1080–6. <https://doi.org/10.1016/j.healun.2017.07.005>; PMID: 28942782.
  11. Jung MH, Gustafsson F. Exercise in heart failure patients supported with a left ventricular assist device. *J Heart Lung Transplant*. 2015;34:489–496. <https://doi.org/10.1016/j.healun.2014.11.001>; PMID: 25577562.
  12. Mirza KK, Cuomo K, Jung MH, et al. Effect of heart rate reserve on exercise capacity in patients treated with a continuous flow left ventricular assist device. *ASAIO J* 2020;66:160–5. <https://doi.org/10.1097/MAT.0000000000000955>; PMID: 30688691.
  13. Hayes K, Leet AS, Bradley SJ, Holland AE. Effects of exercise training on exercise capacity and quality of life in patients with a left ventricular assist device: a preliminary randomized controlled trial. *J Heart Lung Transplant* 2012;31:729–34. <https://doi.org/10.1016/j.healun.2012.02.021>; PMID: 22425235
  14. Kerrigan DJ, Williams CT, Ehrman JK, et al. Muscular strength and cardiorespiratory fitness are associated with health status in patients with recently implanted continuous-flow LVADs. *J Cardiopulm Rehabil Prev* 2013;33:396–400. <https://doi.org/10.1097/HCR.0000000000000024>; PMID: 24189213.
  15. Jakovljevic DG, McDiarmid A, Hallsworth K, et al. Effect of left ventricular assist device implantation and heart transplantation on habitual physical activity and quality of life. *Am J Cardiol* 2014;114:88–93. <https://doi.org/10.1016/j.amjcard.2014.04.008>; PMID: 24925802.
  16. Kerrigan DJ, Williams CT, Ehrman JK, et al. Cardiac rehabilitation improves functional capacity and patient-reported health status in patients with continuous-flow left ventricular assist devices: the Rehab-VAD randomized controlled trial. *JACC Heart Fail* 2014;2:653–9. <https://doi.org/10.1016/j.jchf.2014.06.011>; PMID: 25447348.
  17. Modica M, Ferratini M, Torri A, et al. Quality of life and emotional distress early after left ventricular assist device implant: a mixed-method study. *Artif Organs* 2015;39:220–7. <https://doi.org/10.1111/aor.12362>; PMID: 25205291.
  18. Kiernan MS, Sundareswaran KS, Pham DT, et al. Preoperative determinants of quality of life and functional capacity response to left ventricular assist device therapy. *J Card Fail* 2016;22:797–805. <https://doi.org/10.1016/j.cardfail.2016.01.006>; PMID: 26777757.
  19. Jung MH, Houston B, Russell SD, Gustafsson F. Pump speed modulations and sub-maximal exercise tolerance in left ventricular assist device recipients: a double-blind, randomized trial. *J Heart Lung Transplant* 2017;36:36–41. <https://doi.org/10.1016/j.healun.2016.06.020>; PMID: 27522486.
  20. Jung MH, Goetze JP, Boesgaard S, Gustafsson F. Neurohormonal activation and exercise tolerance in patients supported with a continuous-flow left ventricular assist device. *Int J Cardiol* 2016;220:196–200. <https://doi.org/10.1016/j.ijcard.2016.06.245>; PMID: 2737992.
  21. Dimopoulos S, Diakos N, Tseliou E, et al. Chronotropic incompetence and abnormal heart rate recovery early after left ventricular assist device implantation. *Pacing Clin Electrophysiol* 2011;34:1607–14. <https://doi.org/10.1111/j.1540-8159.2011.03215.x>; PMID: 21950763.
  22. Jakovljevic DG, Birks EJ, George RS, et al. Relationship between peak cardiac pumping capability and selected exercise-derived prognostic indicators in patients treated with left ventricular assist devices. *Eur J Heart Fail* 2011;13:992–9. <https://doi.org/10.1093/eurjhf/hfr069>; PMID: 21719448.
  23. Jacquet L, Vancaenegem O, Pasquet A, et al. Exercise capacity in patients supported with rotary blood pumps is improved by a spontaneous increase of pump flow at constant pump speed and by a rise in native cardiac output. *Artif Organs* 2011;35:682–90. <https://doi.org/10.1111/j.1525-1594.2011.01227.x>; PMID: 21615428.
  24. Hasin T, Topilsky Y, Kremers WK, et al. Usefulness of the six-minute walk test after continuous axial flow left ventricular device implantation to predict survival. *Am J Cardiol* 2012;110:1322–8. <https://doi.org/10.1016/j.amjcard.2012.06.036>; PMID: 22819427.
  25. Noor MR, Bowles C, Banner NR. Relationship between pump speed and exercise capacity during HeartMate II left ventricular assist device support: Influence of residual left ventricular function. *Eur J Heart Fail* 2012;14:613–20. <https://doi.org/10.1093/eurjhf/hfs042>; PMID: 22505397.
  26. Karapolat H, Engin C, Eroglu M, et al. Efficacy of the cardiac rehabilitation program in patients with end-stage heart failure, heart transplant patients, and left ventricular assist device recipients. *Transplant Proc* 2013;45:3381–5. <https://doi.org/10.1016/j.transproceed.2013.06.009>; PMID: 24182820.
  27. Grosman-Rimon L, McDonald MA, Pollock Bar-Ziv S, et al. Chronotropic incompetence, impaired exercise capacity, and inflammation in recipients of continuous-flow left ventricular assist devices. *J Heart Lung Transplant* 2013;32:930–2. <https://doi.org/10.1016/j.healun.2013.05.013>; PMID: 23849515.
  28. Martina J, Jonge N, Rutten M, et al. Exercise hemodynamics during extended continuous flow left ventricular assist device support: The response of systemic cardiovascular parameters and pump performance. *Artif Organs* 2013;37:754–62. <https://doi.org/10.1111/aor.12151>; PMID: 24074245.
  29. Camboni D, Lange TJ, Gansmeier P, et al. Left ventricular support adjustment to aortic valve opening with analysis of exercise capacity. *J Cardiothorac Surg* 2014;9:1–7. <https://doi.org/10.1186/1749-8090-9-93>; PMID: 24884921.
  30. Imamura T, Kinugawa K, Nitta D, et al. Perioperative hypoalbuminemia affects improvement in exercise tolerance after left ventricular assist device implantation. *Circ J* 2015;79:1970–5. <https://doi.org/10.1253/circj.CJ-15-0414>; PMID: 26017065.
  31. Imamura T, Kinugawa K, Nitta D, et al. Opening of aortic valve during exercise is key to preventing development of aortic insufficiency during ventricular assist device treatment. *ASAIO J* 2015;61:514–19. <https://doi.org/10.1097/MAT.0000000000000247>; PMID: 25955152.
  32. Marko C, Danzinger G, Käferbäck M, et al. Safety and efficacy of cardiac rehabilitation for patients with continuous flow left ventricular assist devices. *Eur J Prev Cardiol* 2015;22:1378–84. <https://doi.org/10.1177/2047487314558772>; PMID: 25381335.
  33. Kerrigan DJ, Williams CT, Brawner CA, et al. Heart rate and VO<sub>2</sub> concordance in continuous-flow left ventricular assist devices. *Med Sci Sports Exerc* 2016;48:363–7. <https://doi.org/10.1249/MSS.0000000000000776>; PMID: 26414318.
  34. Jung MH, Houston B, Russell SD, Gustafsson F. Pump speed modulations and sub-maximal exercise tolerance in left ventricular assist device recipients: A double-blind, randomized trial. *J Heart Lung Transplant* 2017;36:36–41. <https://doi.org/10.1016/j.healun.2016.06.020>; PMID: 27522486.
  35. Fresiello L, Buys R, Timmermans P, et al. Exercise capacity in ventricular assist device patients: clinical relevance of pump speed and power. *Eur J Cardiothorac Surg* 2016;50:752–7. <https://doi.org/10.1093/ejcts/ezw147>; PMID: 27174552.
  36. Vignati C, Apostolo A, Cattadori G, et al. LVAD pump speed increase is associated with increased peak exercise cardiac output and vo<sub>2</sub>, postponed anaerobic threshold and improved ventilatory efficiency. *Int J Cardiol* 2017;230:28–32. <https://doi.org/10.1016/j.ijcard.2016.12.112>; PMID: 28038810.
  37. Marko C, Xhelli I, Lackner T, et al. Exercise performance during the first two years after left ventricular assist device implantation. *ASAIO J* 2017;63:408–13. <https://doi.org/10.1097/MAT.0000000000000569>; PMID: 28657929.
  38. Lim HS, Howell N, Ranasinghe A. The effect of left ventricular assist device therapy in patients with heart failure and mixed pulmonary hypertension. *Int J Artif Organs* 2017;40:67–73. <https://doi.org/10.5301/ija.5000556>; PMID: 28315502.
  39. Lairez O, Delmas C, Fournier P, et al. Feasibility and accuracy of gated blood pool SPECT equilibrium radionuclide ventriculography for the assessment of left and right ventricular volumes and function in patients with left ventricular assist devices. *J Nucl Cardiol* 2018;25:625–34. <https://doi.org/10.1007/s12350-016-0670-5>; PMID: 27905008.
  40. Apostolo A, Paoillo S, Contini M, et al. Comprehensive effects of left ventricular assist device speed changes on alveolar gas exchange, sleep ventilatory pattern, and exercise performance. *J Heart Lung Transplant* 2018;37:1361–71. <https://doi.org/10.1016/j.healun.2018.07.005>; PMID: 30195831.
  41. Schmidt T, Bjarnason-Wehrens B, Bartsch P, et al. Exercise capacity and functional performance in heart failure patients supported by a left ventricular assist device at discharge from inpatient rehabilitation. *Artif Organs* 2018;42:22–30. <https://doi.org/10.1111/aor.12936>; PMID: 28621882.
  42. Mezzani A, Pistono M, Agostoni P, et al. Exercise gas exchange in continuous-flow left ventricular assist device recipients. *PLoS One* 2018;13:e0187112. <https://doi.org/10.1371/journal.pone.0187112>; PMID: 29856742.
  43. Rosenbaum AN, Dunlay SM, Pereira NL, et al. Determinants of improvement in cardiopulmonary exercise testing after left ventricular assist device implantation. *ASAIO J* 2018;64:610–5. <https://doi.org/10.1097/MAT.0000000000000693>; PMID: 29045277.
  44. Racca V, Castiglioni P, Panzarino C, et al. Differences in biochemical markers between heart-transplanted and left ventricular assist device implanted patients, during cardiac rehabilitation. *Sci Rep* 2018;8:10816. <https://doi.org/10.1038/s41598-018-29193-0>; PMID: 30018333.
  45. Schmidt T, Bjarnason-Wehrens B, Mommertz S, et al. Development of exercise-related values in heart failure patients supported with a left ventricular assist device. *Int J Artif Organs* 2019;42:201–6. <https://doi.org/10.1177/0391398818815492>; PMID: 30520328.
  46. Gross C, Marko C, Mikl J, et al. LVAD pump flow does not adequately increase with exercise. *Artif Organs* 2019;43:222–8. <https://doi.org/10.1111/aor.13349>; PMID: 30155903.
  47. Koshy A, Cruz NB, Okwose NC, et al. Left ventricular filling pressures contribute to exercise limitation in patients with continuous flow left ventricular assist devices. *ASAIO J* 2020;247–52. <https://doi.org/10.1097/MAT.0000000000001073>; PMID: 31569116.
  48. Gustafsson F, Mirza K, Pyy Y, et al. Predictors of physical capacity six months after implantation of a full magnetically levitated left ventricular assist device: an analysis from the ELEVATE registry. *J Card Fail* 2020;26:580–7. <https://doi.org/10.1016/j.cardfail.2020.04.004>; PMID: 32417377.
  49. Cowger JA, Naka Y, Aaronson KD, et al. Quality of life and functional capacity outcomes in the MOMENTUM 3 trial at 6 months: a call for new metrics for left ventricular assist device patients. *J Heart Lung Transplant* 2018;37:15–24. <https://doi.org/10.1016/j.healun.2017.10.019>; PMID: 29153637.
  50. Jung MH, Hansen PB, Sander K, et al. Effect of increasing pump speed during exercise on peak oxygen uptake in heart failure patients supported with a continuous-flow left ventricular assist device. A double-blind randomized study. *Eur J Heart Fail* 2014;16:403–8. <https://doi.org/10.1002/ejhf.52>; PMID: 24464845.
  51. Mehra MR, Naka Y, Uriel N, et al. A fully magnetically levitated circulatory pump for advanced heart failure. *N Engl J Med* 2017;376:440–50. <https://doi.org/10.1056/NEJMoa1610426>; PMID: 27959709.
  52. Netuka I, Sood P, Pyy Y, et al. Fully magnetically levitated left ventricular assist system for treating advanced HF: a multicenter study. *J Am Coll Cardiol* 2015;66:2579–89. <https://doi.org/10.1016/j.jacc.2015.09.083>; PMID: 26670056.
  53. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. *N Engl J Med* 2007;357:885–96. <https://doi.org/10.1056/NEJMoa067758>; PMID: 17761592.
  54. Krabatsch T, Netuka I, Schmittlo JD, et al. Heartmate 3 fully magnetically levitated left ventricular assist device for the treatment of advanced heart failure – 1 year results from the Ce mark trial. *J Cardiothorac Surg* 2017;12:23. <https://doi.org/10.1186/s13019-017-0587-3>; PMID: 28376837.
  55. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. *N Engl J Med* 2009;361:2241–51. <https://doi.org/10.1056/NEJMoa0909938>; PMID: 19920051.
  56. Aaronson KD, Slaughter MS, Miller LW, et al. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. *Circulation* 2012;125:3191–200. <https://doi.org/10.1161/CIRCULATIONAHA.111.058412>; PMID: 22619284.
  57. Starling RC, Estep JD, Horstmannshof DA, et al. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: the ROADMAP study 2-year results. *JACC Heart Fail* 2017;5:518–27. <https://doi.org/10.1016/j.jchf.2017.02.016>; PMID: 28396040.
  58. Gustafsson F, Shaw S, Lavee J, et al. Six-month outcomes after treatment of advanced heart failure with a full magnetically levitated continuous flow left ventricular assist device: report from the ELEVATE registry. *Eur Heart J* 2018;39:3454–60. <https://doi.org/10.1093/eurheartj/ehy513>; PMID: 30165521.
  59. Rogers JG, Pagani FD, Tatroles AJ, et al. Intrapericardial left ventricular assist device for advanced heart failure. *N Engl J Med* 2017;376:451–60. <https://doi.org/10.1056/NEJMoa1602954>; PMID: 28146651.
  60. Milano CA, Rogers JG, Tatroles AJ, et al. HVAD: the ENDURANCE supplemental trial. *JACC Heart Fail* 2018;6:792–802. <https://doi.org/10.1016/j.jchf.2018.05.012>; PMID: 30007559.
  61. Jung MH, Gustafsson F, Houston B, Russell SD. Ramp study hemodynamics, functional capacity, and outcome in heart failure patients with continuous-flow left ventricular assist devices. *ASAIO J* 2016;62:442–6. <https://doi.org/10.1097/MAT.0000000000000387>; PMID: 27195741.
  62. Imamura T, Kinugawa K, Nitta D, et al. Opening of native aortic valve accomplished after left ventricular assist device implantation in patients with insufficient preoperative beta-blocker treatment. *Int Heart J* 2015;56:303–8. <https://doi.org/10.1536/ihj.14-330>; PMID: 25902887.
  63. Mirza KK, Jung MH, Sigvardsen PE, et al. Computed tomography – estimated right ventricular function and exercise capacity in patients with continuous-flow left ventricular assist devices. *ASAIO J* 2020;66:8–16. <https://doi.org/10.1097/MAT.0000000000000925>; PMID: 30489293.
  64. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. *N Engl J Med* 1991;325:303–10. <https://doi.org/10.1056/NEJM199108013250502>; PMID: 2057035.
  65. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure. *JAMA* 2003;289:2685. <https://doi.org/10.1001/jama.289.20.2685>; PMID: 12771115.
  66. Arnold S V, Jones PG, Allen LA, et al. Frequency of poor outcome (death or poor quality of life) after left ventricular assist device for destination therapy. *Circ Heart Fail* 2016;9:e002800. <https://doi.org/10.1161/CIRCHEARTFAILURE.115.002800>; PMID: 27507111.
  67. Murrinkas D, Alba AC, Delgado D, et al. Right ventricular function and prognosis in stable heart failure patients. *J Card Fail* 2014;20:343–9. <https://doi.org/10.1016/j.cardfail.2014.01.018>; PMID: 24486926.
  68. Villela MA, Guerrero-Miranda CY, Chinnadurai T, et al. Rate response pacing in left ventricular assist device patients. *ASAIO J* 2020;E29–30. <https://doi.org/10.1097/MAT.0000000000000976>; PMID: 30829657.
  69. Muthiah K, Robson D, Prichard R, et al. Effect of exercise and pump speed modulation on invasive hemodynamics in

- patients with centrifugal continuous-flow left ventricular assist devices. *J Heart Lung Transplant* 2015;34:522–9. <https://doi.org/10.1016/j.healun.2014.11.004>; PMID: 256628594.
70. Butler J, Howser R, Portner PM, Pierson RN. Body mass index and outcomes after left ventricular assist device placement. *Ann Thorac Surg* 2005;79:66–73. <https://doi.org/10.1016/j.athoracsur.2004.06.047>; PMID: 15620917.
  71. Go PH, Nemeih HW, Borgi J, et al. Effect of body mass index on outcomes in left ventricular assist device recipients. *J Card Surg* 2016;31:242–7. <https://doi.org/10.1111/jocs.12702>; PMID: 26856974.
  72. Rashid MA, Qureshi BA, Ahmed N, Sherwani MA. Impact of body mass index on left ventricular mass. *J Ayub Med Coll Abbottabad* 2014;26:167–9. PMID: 25603669.
  73. Clerkin KJ, Naka Y, Mancini DM, et al. The impact of obesity on patients bridged to transplantation with continuous-flow left ventricular assist devices. *JACC Heart Fail* 2016;4:761–8. <https://doi.org/10.1016/j.jchf.2016.05.010>; PMID: 27614942.
  74. Amione-Guerra J, Cruz-Solbes AS, Bhimaraj A, et al. Anemia after continuous-flow left ventricular assist device implantation: characteristics and implications. *Int J Artif Organs* 2017;40:481–8. <https://doi.org/10.5301/ijao.5000607>; PMID: 28623639.
  75. Bode LE, Wesner S, Katz JN, et al. Intravenous versus oral iron replacement in patients with a continuous-flow left ventricular assist device. *ASAIO J* 2019;65:E90–1. <https://doi.org/10.1097/MAT.0000000000000904>; PMID: 30312210.
  76. Amione-Guerra J, Cruz-Solbes S, Bhimaraj A, et al. Iron deficiency is the most common cause of anemia in CF-LVAD patients. *Int J Artif Organs* 2017;40:481–8. <https://doi.org/10.5301/ijao.5000607>; PMID: 28623639.
  77. Mardis A, Robinson C, Stafford B, et al. Intravenous iron replacement in patients with left ventricular assist devices. A pilot study. *J Heart Lung Transplant* 2019;38(Suppl):S112–13. <https://doi.org/10.1016/j.healun.2019.01.263>.
  78. Lim HS, Howell N, Ranasinghe A. The physiology of continuous-flow left ventricular assist devices. *J Card Fail* 2017;23:169–80. <https://doi.org/10.1016/j.cardfail.2016.10.015>; PMID: 27989869.
  79. Grosman-Rimon L, Kachel E, McDonald MA, et al. Association between neurohormone levels and exercise testing measures in patients with mechanical circulatory supports. *ASAIO J* 2019. <https://doi.org/10.1097/MAT.0000000000001082>; PMID: 31764006.
  80. Camboni D, Lange TJ, Ganslmeier P, et al. Left ventricular support adjustment to aortic valve opening with analysis of exercise capacity. *J Cardiothorac Surg* 2014;9:93. <https://doi.org/10.1186/1749-8090-9-93>; PMID: 24884921.
  81. Imamura T, Kinugawa K, Nitta D, et al. Novel scoring system using postoperative cardiopulmonary exercise testing predicts future explantation of left ventricular assist device. *Circ J* 2015;79:560–6. <https://doi.org/10.1253/circj.CJ-14-1058>; PMID: 25746540.
  82. Schmidt T, Bjarnason-Wehrens B, Mommertz S, et al. Changes in total cardiac output and oxygen extraction during exercise in patients supported with an HVAD left ventricular assist device. *Artif Organs* 2018;42:22–30. <https://doi.org/10.1111/aor.12936>; PMID: 28621882.
  83. Majani G, Giardini A, Opasich C, et al. Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure trial. *J Card Fail* 2005;11:253–9. <https://doi.org/10.1016/j.cardfail.2004.11.004>; PMID: 15880333.
  84. Spertus J, Peterson E, Conard MW, et al. Monitoring clinical changes in patients with heart failure: A comparison of methods. *Am Heart J* 2005;150:707–15. <https://doi.org/10.1016/j.ahj.2004.12.010>; PMID: 16209970.
  85. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. *Am Heart J* 1992;124:1017–25. [https://doi.org/10.1016/0002-8703\(92\)90986-6](https://doi.org/10.1016/0002-8703(92)90986-6).